Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 5Multiple Myeloma 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Lymphoma 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Platinum-Resistant Fallopian Tube Carcinoma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Neoplasms 1Meningioma 1Melanoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Infratentorial Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

sonidegib 1folfirinox 1Taxes 1Risk Factors 1Oxaliplatin 1Leucovorin 1Irinotecan 1HhAntag691 1Gemcitabine 1Fluorouracil 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Basal Cell × HhAntag691 × 1 year × Clear all
NCT00833417 2026-05-11

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Genentech, Inc.

Phase 2 Completed
104 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡